Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up

British Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 797-800

  Thompson, A M ^a   Crichton, D N ^a   Elton, R A ^b   Clay, M F ^c   Chetty, U ^d   Steel, C M ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; p53; Prognosis; YNZ22

Indexed keywords

MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 17P; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

EID: 0031908182     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.129     Document Type: Article

References (54)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen G, Johnsen H, Varhaug JE, Akslen LA and Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2: 811-814
2. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osbourne CK and McGuire WL (1993) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
3. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L and Borresen A-L (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548
4. Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24: 469-476
5. Bergh J, Norberg T, Sjogren S, Lindgren A and Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034
6. Bland KI, Konstadoulakis MM, Vezeridis MP and Wanebo HJ (1995) Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-720
7. Borg A, Lennerstrand J, Stenmark-Askmalm M, Ferno M, Brisfors A, Ohrvik A, Stal O, Killander D, Lane DP and Brundell J (1995) Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71: 1013-1017
8. Borresen A-L, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, Cornelisse C, Hovig E and Devilee P (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chrom Cancer 14: 71-75
9. Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung B-M, Goodson W, Goldman ES, Moore D, Balazs M, Liu E, Mayall BH and Smith HS (1991) Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 88: 3847-3851
10. Chen TP, Dhingra K, Sahia A, Sneige N, Hortogagyi G and Aldaz CM (1996) Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Br Cancer Res Treat 39: 177-185
11. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D (1988) P53 expression in breast cancer. Int J Cancer 41: 178-183
12. Coles C, Thompson AM, Elder PA, Cohen BB, MacKenzie IM, Cranston G, Chetty U, MacKay J, MacDonald M, Nakamura Y, Hoyheim B and Steel CM (1990) Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336: 761-763
13. Cornelis RS, van Vliet M, Vos CBJ, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Borresen AL, Cornelisse CJ and Devilee P (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumours without p53 mutations. Cancer Res 54: 4200-4206
14. Davidoff AM, Herndonn JE, Glover NS, Kerns BJM, Pence JC, Iglehart JD and Marks JR (1991) Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264
15. Devilee P, van den Broek M, Kuipers-Dukshoorn N, Kolluri R, Khan PM, Pearson PL and Cornelisse CJ (1989) At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics 5: 554-560
16. Elledge RM and Allred DC (1994) The p53 tumour suppressor gene in breast cancer. Br Cancer Res Treat 32: 39-47
17. Elledge RM, Clark GM, Fugua SAW, Yu Y and Allred DC (1994) p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752-3757
18. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC and Allred DC (1995) Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone from breast cancer. J Natl Cancer Inst 87: 1254-1256
19. Friedrichs K, Gluba S, Eidtmann H and Jonat W (1993) Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647
20. Hall PA, Meek D and Lane DP (1996) p53 - Integrating the complexity. J Pathol 180: 1-5
21. Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y and Emi M (1994) Genetic studies of 457 breast cancers: clinicopathologic parameters compared with genetic alterations. Cancer 74: 2281-2286
22. Heisterkamp N, Morris C and Groffen J (1989) ABR, an active BCR-related gene. Nucleic Acids Res 17: 8821-8824
23. Isola J, Visakorpi T, Holli K and Kallioniemi O-P (1992) Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients J Natl Cancer Inst 84: 1109-1114
24. Ito I, Yoshimoto M, Iwase T, Watanabe S, Katagiri T, Harada Y, Kasumi F, Yasuda S, Mitomi T, Emi M and Nakamura Y (1995) Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer 72: 438-441
25. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K and Hirohashi S (1991) Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-840
26. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B and Sommer SS (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 14: 1004-1009
27. Lakhani SR, Collins N, Stratton MR and Sloane JP (1995) Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48: 611-615
28. MacGrogan G, Bonichon F, De Mascarel I, Trojani M, Durand M, Avril A and Coindre J-M (1995) Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Br Cancer Res Treat 36: 71-81
29. Mackay J, Elder PA, Steel CM, Forrest APM and Evans HJ (1988) Allele loss on short arm of chromosome 17 in breast cancers. Lancet ii: 1384-1385
30. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ and Iglehart JD (1994) Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219: 332-341
31. Martinazzi M, Crivelli F, Zampatti C and Martinazzi S (1993) Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 100: 213-217
32. Merlo GR, Venesio T, Bernardi A, Canale L, Gaglia P, Lauro D, Cappa APM, Callahan and Liscia DS (1992) Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumours with high proliferation index. Am J Pathol 140: 215-223
33. Morris C, Benjes S, Haayaja L, Ledbetter DH, Heisterkamp N and Groffen J (1995) Spatial organisation of ABR and CRK genes on human chromosome band 17p13.3. Oncogene 10: 1009-1011
34. Munn KE, Walker RA, Mensce L and Varley JM (1996) Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer 74: 1578-1585
35. Nagai MA, Medeiros A, Brentani MM, Brentani RR, Marques LA, Mazoyer S and Mulligan LM (1995) Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumours. Oncology 52: 448-453
36. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R and Minna JD (1991) Mutations in the p53 gene in primary human breast cancers. Cancer Res 51: 6194-6198
37. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW and Ellis IO (1992) p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66: 583-588
38. Prosser J, Thompson AM, Cranston G and Evans HJ (1990) Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5: 1573-1579
39. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, Wallace M, Wells Jr SA and Donis-Keller HR (1993) Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 53: 2947-2950
40. Runnebaum IB, Nagarajan M, Bowman M, Soto D and Sakumar S(1991) Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657-10661
41. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G and Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970
42. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B and Veronesi U (1996) Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2: 2007-2013
43. Singh S, Simon M, Meybohm I, Jantke I, Jonaf W, Maass H and Goedde HW (1993) Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genetics 90: 635-640
44. Stack M, Jones D, White G, Liscia DS, Venesio T, Casey G, Crichton D, Varley J, Mitchell E, Heighway J and Santibanez-Koref M (1995) Detailed mapping and loss of heterozygosity analysis suggest a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p 13.3. Hum Mol Genet 4: 2047-2055
45. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B and the South East Sweden Breast Cancer Group (1995) p53 as a prognostic factor in stage I breast cancer. Br J Cancer 72: 715-719
46. Takita K, Sato K, Miyagi M, Watatani M, Akiyama H, Sakamoto G, Kasumi F, Abe R and Nakamura Y (1992) Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res 52: 3914-3917
47. Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest APM and Evans HJ (1990) p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 61: 74-78
48. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ and Steel CM (1992) p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50: 528-532
49. Thorlacius S, Borresen A-L and Eyfjord JE (1993) Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53: 1637-1641
50. Tsuda H, Iwaya K, Fukutomi T and Hirohashi S (1993) p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84: 394-401
51. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C and Walker RA (1991) Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6: 413-421
52. Vojtesek B, Bartek J, Midgley CA and Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immun Meth 151: 237-244
53. Wales MM, Biel MA, El Deiry W, Nelkin BD, Issa J-P, Cavenee WK, Kuerbitz, SJ and Baylin SB (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1: 570-573
54. White GRM, Stack M, Santibanezkoref M, Liscia DS, Vensio T, Wang JC, Helms C, Donis-Keller H, Betticher DC, Altermatt HJ, Hoban PR and Heighway J (1996) High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. Br J Cancer 74: 863-867